Skip to main content
AmigoFish

Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD

From Eagle's Eye View: Your Weekly CV Update From ACC.org · · 7 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation.

Back to Eagle's Eye View: Your Weekly CV Update From ACC.org · Report a problem